InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,133.04
(
1.36%
)
US TECH 100
17,432.50
(
2.09%
)
Dow Jones
38,712.61
(
1.27%
)
Brent Oil
82.80
(
-1.00%
)
Bitcoin
61,751.99
(
4.45%
)
Post# of 29291
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119559
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 26728

Wednesday, 01/25/2023 9:14:18 AM

Wednesday, January 25, 2023 9:14:18 AM

Post# of 29291
ABT 4Q22 Results by Business Segment 
  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency)   
 Medical devices*  37%        +7% 
 Diagnostics       33%       -21% 
 Nutrition         18%        -6% 
 Drugs†            12%       +11%
4Q22 COVID-diagnostics sales were $1.07B (32% of total 4Q22 diagnostic sales), down from $1.70B in 3Q22.

58% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up